Guidelines for Drug Donations - Revised 1999
(1999; 24 pages) [French] [Spanish] Ver el documento en el formato PDF
Índice de contenido
Ver el documentoChanges incorporated into the 1999 edition
Ver el documentoI. Introduction
Ver el documentoII. The need for guidelines
Ver el documentoIII. Core principles
Cerrar esta carpetaIV. Guidelines for drug donations
Ver el documentoSelection of drugs
Ver el documentoQuality assurance and shelf-life
Ver el documentoPresentation, packing and labelling
Ver el documentoInformation and management
Abrir esta carpeta y ver su contenidoV. Other ways donors can help
Abrir esta carpeta y ver su contenidoVI. How to implement a policy on drug donations
Ver el documentoAnnex: Examples of problems with drug donations
Ver el documentoAcknowledgements
Ver el documentoReferences
Ver el documentoBack Cover

Information and management

10. Recipients should be informed of all drug donations that are being considered, prepared or actually under way.

Justification and explanation

Many drug donations arrive unannounced. Detailed advance information on all drug donations is essential to enable the recipient to plan for the receipt of the donation and to coordinate the donation with other sources of supply. The information should at least include: the type and quantities of donated drugs including their International Nonproprietary Name (INN) or generic name, strength, dosage form, manufacturer and expiry date; reference to earlier correspondence (for example, the letter of consent by the recipient); the expected date of arrival and port of entry; and the identity and contact address of the donor.

11. In the recipient country the declared value of a drug donation should be based upon the wholesale price of its generic equivalent in the recipient country, or, if such information is not available, on the wholesale world-market price for its generic equivalent.

Justification and explanation

This provision is needed solely to prevent drug donations being valued in the recipient country according to the retail price of the product in the donor country. This may lead to elevated overhead costs for import tax, port clearance and handling in the recipient country. It may also result in a corresponding decrease in the public sector drug budget in the recipient country.

Possible exception

In the case of patented drugs (for which there is no generic equivalent) the wholesale price of the nearest therapeutic equivalent could be taken as a reference.

12. Costs of international and local transport, warehousing, port clearance and appropriate storage and handling should be paid by the donor agency, unless specifically agreed otherwise with the recipient in advance.

Justification and explanation

This provision prevents the recipient from being forced to spend effort and money on the clearance and transport of unannounced consignments of unwanted items, and also enables the recipient to review the list of donated items at an early stage.

Ir a la sección anterior
Ir a la siguiente sección
El Portal de Información - Medicamentos Esenciales y Productos de Salud de la OMS fue diseñado y es mantenido por la ONG Human Info. Última actualización: le 6 diciembre 2017